Home Newsfeeds Needham Maintains Buy on Five Below, Raises Price Target to $188

Needham Maintains Buy on Five Below, Raises Price Target to $188

Needham analyst Bradley Thomas maintains Five Below (NASDAQ:FIVE) with a Buy and raises the price target from $172 to $188.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Needham analyst Bradley Thomas maintains Five Below (NASDAQ:FIVE) with a Buy and raises the price target from $172 to $188.

Microsoft-Activision Adjust Deal Deadline Terms, Goldman Sachs’ Q2 Profits Fall 60%, Johnson & Johnson Joins Legal Battle Against US Government On Drug Pricing Negotiation: Today’s Top Stories

By Vandana Singh

July 19, 10:09 AM

Benzinga What's Going On With Microsoft-Activision Deal? Companies Adjust Deadline Terms

AAL

ImmunityBio Announces Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

By Benzinga Newsdesk

September 19, 10:11 AM

https://clinicaltrials.gov/study/NCT06040918Study OverviewBrief Summary:This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors

IBRX

This Meme Coin Is Up 89%, Outshining Dogecoin, Shiba Inu — Short Sellers Face Liquidations

By Mehab Qureshi

May 15, 1:28 AM

Milady Meme Coin (LADYS) is up 89% in the last 24 hours, outperforming Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB) gains.

$DOGE

MannKind Analyst Turns Bullish, Says ‘Don’t Call It Comeback’

By Priya Nigam

October 10, 12:57 PM

Shares of MannKind Corp (NASDAQ: MNKD) were climbing in early trading on Tuesday.

MNKD

Needham Maintains Buy on Five Below, Raises Price Target to $188

Related Posts

Microsoft-Activision Adjust Deal Deadline Terms, Goldman Sachs’ Q2 Profits Fall 60%, Johnson & Johnson Joins Legal Battle Against US Government On Drug Pricing Negotiation: Today’s Top Stories

ImmunityBio Announces Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

This Meme Coin Is Up 89%, Outshining Dogecoin, Shiba Inu — Short Sellers Face Liquidations

MannKind Analyst Turns Bullish, Says ‘Don’t Call It Comeback’